WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the closing of its upsized underwritten public offering of $602.0 million of shares of its common stock. Kymera sold and issued 8,050,000 shares of its common stock, which includes 1,050,000 shares sold and issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock. The shares of common stock were sold at a public offering price of $86.00 per share. The gross proceeds to Kymera from the offering were approximately $692.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera.

Morgan Stanley, J.P. Morgan, Jefferies, Stifel, Guggenheim Securities and Wells Fargo Securities acted as joint book-running managers for the offering.

The securities described above were offered pursuant to an automatically effective shelf registration statement on Form S-3 (No. 333-282912) that was filed with the U.S. Securities and Exchange Commission (the "SEC") on October 31, 2024. The offering was made only by ...